Next week could usher in the beginning of a new era as the world's biggest blockbuster drug meets biosimilar competition for the first time in Europe. Under nonexclusive licensing agreements with Abbvie Inc., of North Chicago, at least three biosimilars to Humira (adalimumab) can begin taking flight, beginning Tuesday, in the 28 member states of the EU, as well as Iceland, Lichtenstein and Norway. Read More
Trevena Inc. came out swinging at Thursday's advisory committee meeting, but it was unable to score even a technical knockout with oliceridine, a novel injectable opioid receptor mu agonist developed to treat moderate to severe acute pain. Read More
Not unlike the zeal of trainspotters, the allure of chimeric antigen receptor T cell (CAR T) therapy continues to attract devoted fans. And biopharma investors clearly expect the former management team at Kite Pharma Inc. to keep that train rolling down the track. Read More
DUBLIN – Carrick Therapeutics Ltd. in-licensed a clinical-stage ovarian cancer drug from BTG plc, which it is now planning to move into pivotal studies. Deal terms were not disclosed. Read More
LONDON – Midatech plc has ditched its plan to develop a specialty pharma arm, selling off the U.S. cancer palliative care business to focus on applying its nanodelivery technologies to developing new drugs. Read More
HONG KONG – China's State Medical Insurance Administration has added 17 cancer drugs to the National Reimbursement Drug List (NRDL) covered by its national basic health insurance, work-related injury insurance and maternity insurance this week, slashing their prices as much as 74 percent. Read More
Themis Bioscience GmbH, of Vienna, licensed worldwide rights to an oncolytic measles virus platform from Max-Planck-Innovation GmbH, of Munich. The platform was jointly developed by the Eberhard-Karls-University Tübingen and the Max Planck Institute for Biochemistry. Terms of the deal weren't disclosed. Read More
Histogenics Corp., of Waltham, Mass., said it closed its underwritten public offering of 26.15 million shares and warrants to purchase up to 19.61 million shares at a combined purchase price of 65 cents per share and accompanying warrant. The net proceeds are approximately $15.4 million. Read More
